Andrea Mastrostefano

Dr. Andrea Mastrostefano

orcid
Department of Physiology and Pharmacology, Sapienza Universi...

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
GCGabriele Di Cicco
Gabriele Di Cicco
EMEmanuela Marzano
Emanuela Marzano
AMAndrea Mastrostefano
Andrea Mastrostefano
ARAlessandro Rizzi
Alessandro Rizzi
RCRodrigo Simões Castilho
Rodrigo Simões Castilho
Carlo PerisanoCarlo Perisano
Carlo Perisano
Background: Osteoarthritis (OA) is the most common degenerative joint disease and affects millions of people worldwide, particularly the elderly population. The pathophysiology of OA is complex and involves multiple factors. Methods: Several studies have emphasized the crucial role of inflammation in this process. The receptor activator of NF-κB ligand (RANKL), the receptor activator of NF-κB (RANK), and osteoprotegerin (OPG) trigger a signaling cascade that leads to the excessive production of RANKL in the serum. Conclusions: The aim of this narrative review is (i) to assess the role of the RANK/RANKL/OPG signaling pathway in the context of OA progression, focusing especially on the physiopathology and on all the mechanisms leading to the activation of the inflammatory cascade, and (ii) to evaluate all the potential therapeutic strategies currently available that restore balance to bone formation and resorption, reducing structural abnormalities and relieving pain in patients with OA.

23 September 2025 in Legal Medicine
Verified
Journal Article
Open access
EPEnrico Pilia
Enrico Pilia
AMAndrea Mastrostefano
Andrea Mastrostefano
TGTommaso Germanò
Tommaso Germanò
GAGiuseppe Amato
Giuseppe Amato
GCGozzelino Camilla
Gozzelino Camilla
ACAlberto Chighine
Alberto Chighine
The post-mortem diagnosis of fatal anaphylaxis presents significant challenges due to the absence of pathognomonic findings. Serum tryptase has been proposed as a potential biomarker to support forensic diagnosis, but optimal post-mortem thresholds remain undefined. This systematic review investigates the sensitivity and specificity of post-mortem blood tryptase in diagnosing fatal anaphylaxis. We conducted a systematic literature review adhering to the PRISMA guidelines, with searches across major databases. Studies published between 1990 and 2024 were screened to identify those addressing fatal anaphylactic shock, applying strict inclusion criteria to ensure relevance. A total of 20 studies met our criteria, representing 1033 individuals, including 221 anaphylactic deaths. Sensitivity and specificity of tryptase were analyzed using various thresholds, with data synthesis conducted using the Mann-Whitney-Wilcoxon test and ROC analysis to identify optimal diagnostic cut-offs. Our findings demonstrated that the cut-off of 30.4 ng/mL proposed by the most recent meta-analysis offers a balanced sensitivity (88.20 %) and specificity (87.00 %). Sensitivity remains stable across tryptase values ranging from 30 to 60 ng/mL, while specificity tends to increase. Youden's J index was applied to identify the cut-off with the optimal combination of sensitivity and specificity, namely 74.2 ng/mL. Additionally, Negative Likelihood Ratio allowed to identify 12.00 ng/mL as the cut-off at which the possibility of an anaphylactic death can be ruled out. This review highlights the optimal balance of sensitivity and specificity of post-mortem blood tryptase enhancing forensic diagnostic accuracy for fatal anaphylaxis cases.

8 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAndrea Mastrostefano
Andrea Mastrostefano
GGGiuseppe Greco
Giuseppe Greco
CBChiara De Bacco
Chiara De Bacco
FDFlavio Davini
Flavio Davini
GPGiacomo Polito
Giacomo Polito
STSergio Terracina
Sergio Terracina
Alcohol Use Disorder (AUD) is a global social burden, with alcohol being the most prevalent psychoactive substance used by older individuals. Alcohol intake is a recognized carcinogen and is regulated by alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs), with activity and expression determined by genetic factors. Alcohol withdrawal challenges include tremors, diaphoresis, anxiety, sleeplessness, hallucinations, and convulsions. Alcohol also stimulates cholinergic interneurons and increases the sensitivity of 5-HT3 receptors within the nucleus accumbens, which play a critical role in reward and addiction. Chronic alcohol consumption alters the mesolimbic dopaminergic system, an important neural pathway involved in reward processing. First-line pharmacotherapies for AUD include oral naltrexone and acamprosate, disulfiram, and nalmefene. Off-label therapies include baclofen, topiramate, gabapentin, ondansetron, and cytisine. Understanding altered neuronal signaling pathways by alcohol helps identify effectors involved in mitigating central actions and offers new therapeutic perspectives for alcohol addiction rehabilitation.

11 July 2025 in Targets
Verified
Journal Article
Open access
PDF file
AMAndrea Mastrostefano
Andrea Mastrostefano
GGGiuseppe Greco
Giuseppe Greco
CBChiara De Bacco
Chiara De Bacco
FDFlavio Davini
Flavio Davini
GPGiacomo Polito
Giacomo Polito
STSergio Terracina
Sergio Terracina
Alcohol is a prevalent psychoactive substance and a risk factor for developing injuries and non-communicable diseases, representing a significant health and economic burden. Alcohol involves numerous molecular pathways. Its metabolism is regulated by alcohol dehydrogenases and aldehyde dehydrogenases; it also stimulates cholinergic interneurons, increasing the sensitivity of 5-HT3 receptors, while chronic alcohol consumption alters the mesolimbic dopaminergic system involved in reward processing. The treatment of alcohol use disorder (AUD) is essential to manage complex patients, following an evidence-based approach. The aim of this narrative review is to provide a clear and practical summary to support and assist healthcare professionals in the Italian context. Approved pharmacological treatments for AUD include oral naltrexone and acamprosate, sodium oxybate, disulfiram, and nalmefene. Off-label therapies include baclofen, topiramate, gabapentin, pregabalin, ondansetron, and cytisine. A more informed clinical and practical approach that understands the altered neuronal signaling pathways is essential for offering effective, efficient, appropriate, and safe therapeutic algorithms for complex patients with alcohol use disorder. A comprehensive framework should include integrated treatments with a personalized approach.

19 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
DDDanial Daroui
Danial Daroui
AMAndrea Mastrostefano
Andrea Mastrostefano
FDFlavio Davini
Flavio Davini
GGGreco Giuseppe
Greco Giuseppe
STSergio Terracina
Sergio Terracina
Background: Alcohol Use Disorder (AUD) is a chronic pathological condition with significant burdens throughout the world. Despite the effectiveness of the current pharmacological treatments, the ongoing issues with AUD and the high relapse rates necessitate the exploration of innovative therapies, including the use of psychedelic drugs, which have shown promising initial results. The purpose of the current study is to map the evidence on potential uses of psilocybin and its neurobiological pathways, highlighting gaps in knowledge and suggesting research opportunities. Methods: A scoping review of the literature was performed according to the population, concept, and context (PCC) framework. Data were synthesized in tabular form to summarize key study characteristics. Results and discussion: After screening 757 records, we included 12 studies published between 1968 and 2025: 7 RCTs, 4 open-label studies, and 1 case report. Early Polish studies suggested long-term remission of alcohol cravings, while recent U.S.-based RCTs showed that psilocybin, when paired with psychotherapy, reduced heavy drinking days and alcohol-related and mental problems. Limitations have been identified in small sample sizes and short follow-up periods in patient safety data, particularly in those with comorbidities. Most of the studies have been carried out in a hospital and university psychiatry department setting involving physicians and psychologists. Conclusion: Psilocybin has emerged as a promising and innovative compound for the treatment of AUD in an experimental phase. Future research should be conducted to assess pharmacological effects, efficacy, and patient safety through rigorous RCTs across diverse populations. To achieve better outcomes, it is essential to address drug development and pharmaceutical legislation regarding safe therapeutic algorithms.

1 June 2026 in Targets
Verified
Journal Article
Open access
PDF file
RGRiccardo Gennari
Riccardo Gennari
NCNicole CAPRETTI
Nicole CAPRETTI
DDDanial Daroui
Danial Daroui
STSergio Terracina
Sergio Terracina
LMLorenzo Martellone
Lorenzo Martellone
GGGiuseppe Greco
Giuseppe Greco
Gambling disorder (GD) constitutes a worldwide social and economic burden and is associated with impaired functioning and reduced quality of life. GD shares important mechanistic substrates with obsessive–compulsive disorder (OCD), including dysfunction of cortico-striato-thalamo-cortical circuitry and dysregulation of serotonergic pathways involved in impulsivity, compulsivity, and impaired inhibitory control. On this basis, selective serotonin reuptake inhibitors (SSRIs), widely used in several psychiatric disorders, have been investigated as potential pharmacological treatments for GD. Evidence concerning fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram is heterogeneous and overall limited. Some early single-blind, randomized, and open-label studies have reported reductions in gambling urges, severity, and compulsive symptoms. However, larger and more rigorous placebo-controlled trials have frequently failed to demonstrate consistent superiority over placebo. Interpretation of these findings is further limited by small sample sizes, short observation periods, high dropout rates, heterogeneous outcome measures, and substantial placebo response. While SSRIs remain biologically plausible candidates for modulating the compulsive and impulsive dimensions of GD, current evidence does not support their routine use as first-line pharmacological treatment. Their role appears most justified in the presence of psychiatric comorbidity or within individualized, phenotype-oriented treatment strategies.